ArticleEuropean journal of medical research2025
Statin use is associated with reduced delirium and improved short-term outcomes in critically ill patients with chronic kidney disease.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDelirium is a common and serious neurocognitive complication in critically ill patients, particularly those with chronic kidney disease (CKD), who are predisposed due to systemic inflammation, metabolic dysregulation, and polypharmacy. Statins, widely used for their cardiovascular benefits, also possess anti-inflammatory and neuroprotective properties that may influence delirium risk. However, their impact on delirium incidence and short-term prognosis in CKD patients remains unclear.
methodsWe conducted a retrospective cohort study using the MIMIC-IV database, identifying 3218 adult patients with CKD admitted to the intensive care units (ICU). Patients were stratified based on statin exposure during the 3 days before and after ICU admission. The primary outcome was the incidence of delirium, which was assessed using the Confusion Assessment Method for the ICU (CAM-ICU). Secondary outcomes included all-cause mortality at 30 days and 90 days. Propensity score matching (PSM) was employed to balance baseline characteristics, and multivariable logistic and Cox regression models were utilized to estimate associations.
resultsBefore matching, statin use was associated with significantly lower delirium incidence (25.0% vs. 34.4%, p < 0.001) and lower 30-day mortality (20.4% vs. 28.7%, p < 0.001). After 1:1 PSM (n = 2132), these associations remained significant: statin use correlated with reduced odds of delirium (adjusted OR 0.60, 95% CI 0.49-0.74, p < 0.001), and lower 30-day (HR 0.82, 95% CI 0.69-0.97, p = 0.019) and 90-day mortality (HR 0.80, 95% CI 0.69-0.93, p = 0.003). Subgroup analyses showed consistent findings across CKD stages and comorbidity profiles, with notable interaction observed in benzodiazepine users (interaction for p = 0.009).
conclusionAmong critically ill patients with CKD, statin use is independently associated with a lower risk of delirium and improved short-term survival. These findings support the potential neuroprotective role of statins in this high-risk population and warrant further investigation through prospective studies and randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.